Breaking
European Research Revolution: Day 1 HighlightsRAPS Euro Convergence: Key Regulatory Updates - Day 1Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD
🇪🇺 EMA

Mergers & Acquisitions

Page 1 • 1 item

Track global pharma M&A deals, divestitures, and partnerships. Gain critical intelligence for strategic investment and business development in life sciences.

Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Operations
NewsPainMay 4, 2026

Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Operations

Purdue Pharma, the manufacturer of OxyContin, is ceasing operations following a $7.4 billion settlement agreement. This landmark deal aims to address the company's role in the opioid crisis and provide compensation to victims.

Dr. Priya Nandakumar